CDC Report Addresses Vaccine Efficacy in Immunocompromised Persons

November 5, 2021

In this week’s Morbidity and Mortality Weekly Report (MMWR), the CDC addressed COVID-19 vaccine efficacy in immunocompromised persons. Studies and clinical data suggest that immunocompromised persons who receive COVID-19 vaccines may not develop robust antibodies, and may not be protected against severe COVID-19 like immunocompetent persons who have been vaccinated. In a retrospective analysis of 20,000 hospitalized COVID cases, immunocompromised persons given two doses of an mRNA vaccine mounted 77% efficacy against COVID-19 hospitalization. Patients with rheumatic and inflammatory disorders were included in this cohort. MRNA vaccines in immunocompetent adults (as part of the control group) demonstrated 90% efficacy. “This difference persisted irrespective of mRNA vaccine product, age group, and timing of hospitalization relative to SARS-CoV-2.” Use of immunosuppressive therapies was not collected for data analysis.

The median age of immunocompetent and immunocompromised patients was 68 years and 70 years, respectively. “Among immunocompetent patients, 42% had received the Moderna vaccine and 58% had received the Pfizer-BioNTech vaccine, and among immunocompromised patients, 41% and 59% had received Moderna and Pfizer-BioNTech vaccines, respectively.” Among immunocompetent patients, the median time between receiving the second dose of the Moderna vaccine and hospital admission was 89 days; this increased to 90 days for Pfizer vaccine recipients. Among immunocompromised patients, intervals were 89 days for both Moderna and Pfizer vaccine recipients.

Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.